Is Septerna, Inc. Common Stock (SEPN) overvalued? · rev $1.1M
Septerna, Inc. Common Stock (SEPN) is a biotechnology company listed on NASDAQ.
This page asks whether Septerna, Inc. Common Stock (SEPN) looks expensive on cached numbers — not a short thesis.
Latest reported SEPN revenue for 2024-12-31 was $1.1M. Net income was -$71.8M. Revenue was up 611.9% from 2023-12-31 to 2024-12-31. SEPN currently screens at market cap $1.61B.
SEPN currently screens at market cap $1.61B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SEPN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SEPN stock page for the full model, not this heading.
Not investment advice.